Abstract
Objective: To investigate protamine sulfate inhibition of expression of the vascular endothelial growth factor (VEGF) and VEGF-VEGFR binding in vitro and to find a new drug that inhibits neovascularization, which can potentially be used to treat angiogenic eye diseases such as diabetic retinopathy and age-related macular degeneration (AMD).
Methods: Monkey retinal vascular endothelial cells (RF/6A) were cultured in vitro and different concentrations of protamine sulfate were added to the vascular endothelial cells after three passages. VEGF expression level was examined by ELISA and immunohistochemistry after the cells were treated with protamine sulfate.
Results: VEGF expression decreased in a dose-dependent pattern in 10–80 μg/ml of protamine sulfate. We also found that protamine sulfate could inhibit VEGF to bind to its receptor, VEGFR.
Conclusion: Protamine sulfate could inhibit VEGF expression and VEGF-VEGFR binding in vitro. Protamine sulfate may be used for inhibiting neovascularization in angiogenic eye diseases.
Angiogenic eye diseases such as diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinal vein occlusion are the main blindness-causing diseases. Previous studies indicated that VEGF and its receptor were involved in the pathogenesis, development and prognosis of these diseases. VEGF inhibition drugs have been used successfully in clinical treatment, but the cost is prohibitive.
Protamine sulfate is a common, inexpensive anti-coagulation drug widely used for anti-coagulation in cases when heparin has been overused in the clinic. Recent studies suggest that protamine sulfate can inhibit tumor growth, probably through inhibiting vascular growth of the tumor. In this study we showed that protamine sulfate could inhibit VEGF and the binding of VEGF and its receptor, implying that protamine sulfate may inhibit blood vessel growth through inhibition of the VEGF pathway. This study further suggested that protamine sulfate may be potentially used to treat angiogenic eye diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barfod NM, Larsen B (1974) Increased growth-inhibiting effect on tumour cells of protamine sulfate after Polymerization. Eur J Cancer 10(11):765–769
Eichler W, Yafai Y, Wiedemann P et al (2004) Angiogenesis-related factors derived from retinal glial (Müller) cells inhypoxia. Neuroreport 15(10):1633–1637
Forooghian F, Razavi R, Timms L (2007) Hypoxia-inducible factor expression in human RPE cells. Br J Ophthalmol 91(10):1406–1410
Gilbert RE, Vranes D, Berka JL et al (1998) Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 78(8):1017–1027
Heiduschka P, Julien S, Hofmeister S et al (2008) Bevacizumab (Avasin) does not harm retinal function after intravireal injection as shown by electrorenitography in abult mice. Retina 28(1):46–55
Wu WC, Kao YH, Hu PS et al (2007) Geldanamycin, a HSP90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro. Exp Eye Res 85(5):721–773
Acknowledgments
The Study was supported by the National Natural Foundation of China; Sichuan Provincial Foundation for People Coming Back from Studying Abroad; Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hu, J., Qu, C., Yu, Y., Ping, M., Wei, D., Dandan, D. (2010). Protamine Sulfate Downregulates Vascular Endothelial Growth Factor (VEGF) Expression and Inhibits VEGF and Its Receptor Binding in Vitro. In: Anderson, R., Hollyfield, J., LaVail, M. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 664. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1399-9_39
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1399-9_39
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1398-2
Online ISBN: 978-1-4419-1399-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)